Table 1.

Literature included in the report

Author	Year	Report section	Country	Strategies	DAA or interferon	ICER	Citation
Castelnuovo	2006	Persons who inject drugs	UK	Compared focused case-finding to background testing	Interferon	16,514£/QALY	[10]
Selvapatt	2017	Persons who inject drugs	UK	Compared testing and treatment in a drug treatment unit to no testing and no treatment	DAA	1029£/QALY	[11]
Loubiere	2003	Persons who inject drugs	France	Compared testing with EIA to no testing	Interferon	3825€/QALY	[12]
Leal	1999	Persons who inject drugs	UK	Compared testing and treating PWID to no testing and no treatment	Interferon	9300£/QALY	[13]
Stein	2004	Persons who inject drugs	UK	Compared testing and treating PWID to no testing and no treatment	Interferon	28,000£/QALY	[14]
Thompson Coon	2006	Persons who inject drugs	UK	Compared focused case-finding to background testing	Interferon	16,000£/QALY	[15]
Schackman	2015	Persons who inject drugs	US	Compared on-site and off-site HCV testing offer in a substance abuse treatment program to no HCV testing offer	Both	18,300$/QALY	[16]
Cipriano	2012	Persons who inject drugs	US	Compared several different interval testing strategies for HCV and HIV compared to no testing	Interferon	168,600$/QALY	[17]
Martina	2013	Persons who inject drugs	UK	Compared dried blood spot HCV testing to no testing in addiction services	Interferon	14,600£/QALY	[18]
Martina	2013	People in prison	UK	Compared dried blood spot HCV testing to no testing in prison	Interferon	59,400£/QALY	[18]
Sutton	2008	People in prison	UK	Compared testing in prison to testing only in the community	Interferon	54,852£/QALY	[19]
Martin	2016	People in prison	UK	Compared increased case-finding in prisons to background testing	DAA	15,090£/QALY	[20]
He	2016	People in prison	US	Compared risk-based opt-out testing in prison to no testing	DAA	29,234$/QALY	[21]
Sutton	2006	People in prison	UK	Compared four case-finding scenarios on intake to prison to no case finding efforts	N/A	£6388/case identified	[22]
Linas	2012	HIV-infected MSM	US	Compared interval testing to symptom-based testing	Interferon	57,800$/QALY	[23]
Nakamura	2008	Birth cohort	Japan	Compared national testing programs to no testing, stratified by age group	Interferon	848$-4825$/QALY	[24]
Coffin	2012	Birth cohort	US	Compared testing of individuals born between 1945 and 1965 to general population testing	Interferon	5400$/QALY	[25]
McEwan	2013	Birth cohort	US	Compared testing of individuals born between 1945 and 1965 to risk-based testing	Interferon	28,602$/QALY	[26]
McGarry	2012	Birth cohort	US	Compared testing of individuals born between 1946 and 1970 to risk-based testing	Both	37,700$/QALY	[27]
Rein	2012	Birth cohort	US	Compared testing of individuals born between 1945 and 1965 to the standard of care	Both	35,700$/QALY	[28]
Liu	2013	Birth cohort	US	Compared testing of individuals aged 40–64 to no testing	Interferon	65,749$/QALY	[29]
Wong	2015	Birth cohort	Canada	Compared testing and treatment to no testing and no treatment in 45–64 year olds	Both	36,471$/QALY	[30]
Ruggeria	2013	Birth cohort	Italy	Compared testing to no testing, stratified by age	Interferon	1383–10,432€/QALY	[31]
Ruggeria	2013	General population	Italy	Compared testing to no testing	Interferon	5171€/QALY	[31]
Eckman	2013	General population	US	Compared testing and treatment to no testing or treatment	DAA	47,276$/QALY	[32]
Deuffic-Burban	2009	General population	France	Compared different follow-up schedules for detection of occupational HCV infection	Interferon	€2020/QALY	[33]
Miners	2014	General population	UK	Compared elevated testing of migrants to the UK to the current background rate of testing	Interferon	£23,200/QALY	[34]
Kim	2015	General population	Egypt	Compared testing and treatment to no testing or treatment	Both	Cost saving	[35]

^aArticles appearing twice contained sub-analyses covering multiple populations